Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Narrative) (Details)

v3.24.1
Intangible Assets (Narrative) (Details)
$ in Thousands
 1 Months Ended 12 Months Ended 24 Months Ended
Jul. 31, 2020
USD ($)
Jul. 31, 2020
USD ($)
Milestone
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Finite-Lived Intangible Assets [Line Items]          
Asset impairment     $ 3,100    
Purchase of intangible asset     5,000 $ 0  
Payments of milestones         $ 500
Journey          
Finite-Lived Intangible Assets [Line Items]          
Asset impairment     $ (3,143) $ 0  
Journey | Dr. Reddy's Laboratories, Ltd          
Finite-Lived Intangible Assets [Line Items]          
Purchase of intangible asset   $ 5,000      
Payment of Upfront Fees   1,000      
Payments of milestones   $ 4,000      
Accutane agreement 10 years        
Period of written notice 180 days        
Achievement of Certain Sales Milestones | Journey | Dr. Reddy's Laboratories, Ltd          
Finite-Lived Intangible Assets [Line Items]          
Payments of milestones $ 17,000        
Number of development milestones | Milestone   3      
Qbrexza | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Percentage of royalty amounts diminution in the event of loss of exclusivity   50.00%      
Qbrexza | Achievement of Certain Sales Milestones | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Payments of milestones   $ 144,000      
Qbrexza | Minimum | First Two Years | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Asset purchase agreement, percentage of royalties   30.00%      
Qbrexza | Minimum | Period of Eight Years, After First Two Years | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Asset purchase agreement, percentage of royalties   12.00%      
Qbrexza | Maximum | First Two Years | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Asset purchase agreement, percentage of royalties   40.00%      
Qbrexza | Maximum | Period of Eight Years, After First Two Years | Journey | Dermira, Inc. a subsidiary of Eli Lilly          
Finite-Lived Intangible Assets [Line Items]          
Asset purchase agreement, percentage of royalties   19.00%